A comparative study on the effects of diet and exercise, metformin and metformin + pioglitazone treatment on NIDDM patients

Indian Journal of Clinical Biochemistry

Volumn 22, Issue 2, 2007, Pages 65-69

  Augusti, K T ^a,c   Sunil, N P ^a   Abraham, Andrews ^a   Thomas, Sajimon ^a   Chemmanam, Varghese ^b  

^a School of Medical Education   (India)

^b Medical Centre Hospital   (India)

^c KANNUR UNIVERSITY   (India)

Author keywords

Diet cum exercise; Enzymes; FBS; Hb A 1c; Metformin; NIDDM patients; Pioglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

EID: 36849082145     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02913316     Document Type: Article

References (26)

1. Grundy SM. Dietary therapy in diabetes mellitus: Is their a single best diet? Diabetes Care 1991; 14: 796-801.
2. Pan X, Huy. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20(4):537-44.
3. Labovitz HE. Non-Insulin dependent (type II ) diabetes mellitus, In: Krishna Berg RA(eds). Diabetes Mellitus. La Jolla, Calif: Publishers National Health Laboratory 1992: 16-25.
4. Marshall JA, Hamman RF, Baxter J. High fat low carbohydrate diet and etiology of non-insulin dependent diabetes mellitus: The San Luis Valley Diabetes study. Am J Epidemiol 1991 ; 134: 590-603.
5. National Research Council : Diet and Health. Implications for reducing chronic disease risk. National Academy Press, Washington DC1989.
6. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of Non-Insulin dependent diabetes mellitus. N Engl Med 1991; 325:147-52.
7. Horton ES. Exercise and decreased risk of NIDDM. N Engl J Med 1991; 325: 196-8.
8. th edn by Satoskar RS, Bhandorkar SD. Chapter 60. P. 806. Insulin and Oral anti-diabetic drug.
9. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755-72.
10. UK Prospective Diabetes Study group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type II diabetes. Lancet 1998; 352: 854-66.
11. Moses R, Slobodnuik R, Donnelly T. Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin (abstr.) Diabetes 1997; 46(suppl.1) : 93A.
12. Purnell JQ, Hirsch IB. New oral therapies for type 2 diabetes. Am Fam Physician 1997;56: 1835-42.
13. Salral AR, Olesfasky J. Thiazolidine diones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996; 45(12): 1661-69.
14. Ertel NH. New therapeutic agents for type 2 diabetes : In managing type 2 diabetes. Postgraduate Medicine Special report March 1998; 25-32.
15. Olesfasky J, Ravazzalo M, Kailsaram. Oral hypoglycemic agents in diabetic subject. Diabetes Care 1976; 14: 312-28.
16. Glucose-oxidase methods In: Microanalysis in Medical Biohemistry, 4th ed.I.D.P. Wootion, Ed.(J and A Churchill Ltd. London) 1964. P.96.
17. Van Kampen EJ, Zijlstra WG. Standardization of hemoglobinometry II. The hemiglobincyanide method. Clin. Chem Acta 1961; 6(4): 538-44.
18. Bergmeyer HU. Standardization of Enzyme Assays. Clin Chem 1972; 18: 1305-11.
19. Horder M, Rej R. Alanine transaminase, in methods of enzymatic analysis. 3rd edn. Edited by H.Bergmeyer, J. Bergmeyer and M. Grassl, Weinheim Verlag Chemie, Basel 1983, 444.
20. Kulhanik V, Dimov DM. A new useful modification for the determination of gamma-glutamyl transferase activity. Clin Chem Acta 1966; 14(5): 619-23.
21. National Institute for Clinical Excellence: Guidance on the use of pioglitazone for type 2 diabetes mellitus. Technology appraisal guidance No. 21. March 2001.
22. King AB. A comparison in a clinical setting of the three thiazolidine diones(letter). Diabetes care 2000; 23: 557.
23. Aronoff S, Rosenblatt S, Braith WS, Egan JW, Mathisen AL, Schnieder RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes, a six months randomized placebo-controlled dose-response study group. The pioglitazone 001 study group. Diabetes Care 2000; 23: 1605-11.
24. Tack C, Demacker P, Stairs P, Stalenhoef A, Trioglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796-9.
25. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E Bertone G, Cicarelli L, Piccinni MN. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride : a Twelve month, multicenter, double-beind, randomized, cortrolled, parallel group trial. Clin Ther 2004; 26(5): 744-54.
26. Mattoo V, Eckland D, Widel M, Duarn S, Fajardo C, Strand J et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of six months randomized, double blind, prospective, multicentre, parallel group study. Clin Ther 2005; 27(5): 554-67.